Brandon Coyle
Director of Pivotal Process Development Gilead
Brandon Coyle is Director of Pivotal Downstream Process Development at Gilead Sciences, specializing in antibody-drug conjugates (ADCs). He leads pivotal process development and commercial tech transfers, with expertise in conjugation and purification strategies. Brandon has authored key regulatory submissions, holds multiple patents, and has driven innovations that significantly reduced manufacturing costs. \he brings deep experience in CMC, QbD, and technology transfer. He earned his PhD in Chemical Engineering from the University of Washington.
Seminars
Wednesday 10th June 2026
Payload-Linker Impurities & Their Outsized Impact on ADC Product Quality During Conjugation & Purification
3:30 pm
- Discover how minor drug-linker (DL) impurities can significantly impact ADC quality
- Discuss how current impurity control strategies may be insufficient and need to be established holistically with and end-to-end mindset
- Highlight case studies demonstrating how DL impurities impact conjugation outcomes
